

Applicants: Ilya Trakht et al.
Serial No.: 09/664,958
Filed: September 18, 2000
Page 2

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the specification:

Listing of Claims:

Claims 1-6. (canceled)

Claim 7. (original): The monoclonal antibody 27.B1 produced by hybridoma 27.B1 (ATCC Designation No. PTA-1599).

Claim 8. (cancelled)

Claim 9. (previously presented): The hybridoma cell designated 27.B1 (ATCC Accession No. PTA-1599).

Claims 10-16. (canceled)

Claim 17. (original): The monoclonal antibody 27.F7 produced by hybridoma 27.F7 (ATCC Designation No. 1598).

Claim 18. (previously presented): The hybridoma cell designated 27.F7 (ATCC Accession No. PTA-1598).

Claims 19-174. (canceled)

Claims 175-180. (canceled)

Claim 181. (currently amended): A kit for detecting the presence of TIP-2-bearing cancer cells in a sample comprising:

Applicants: Ilya Trakht et al.
Serial No.: 09/664,958
Filed: September 18, 2000
Page 3

a) a solid support having a plurality of immobilized probes which may be the same or different, wherein each probe comprises a monoclonal antibody or Fab fragment thereof which specifically binds and forms a complex with TIP-2 located on the surface of human cancer cells; and

b) a means for determining the presence of the probe/TIP-2 complex ~~The kit of claim 176,~~
wherein the probe is human monoclonal antibody 27.B1 produced by hybridoma 27.B1 (ATCC Designation No. PTA-1599) or human monoclonal antibody 27.F7 produced by hybridoma 27.F7 (ATCC Designation No. PTA-1598).

6
Claim 182.

(currently amended): The kit of claim 176 ~~181~~, wherein the means for determining the presence of the probe/TIP-2 complex comprises a detectably labeled antibody.

7
Claim 183.

(currently amended): The kit of claim 176 ~~181~~, wherein the means for determining the presence of the probe/TIP-2 complex comprises a detectably labeled antibody which specifically binds to a ~~monoclonal antibody directed to TIP-2~~ human monoclonal antibody 27.B1 produced by hybridoma 27.B1 (ATCC Designation No. PTA-1599) or human monoclonal antibody 27.F7 produced by hybridoma 27.F7 (ATCC Designation No. PTA-1598).

8
Claim 184.

(previously presented): The kit of claim 182 or 183, wherein the detectable label is a radioactive isotope, enzyme, dye, biotin, fluorescent label or chemiluminescent label.